Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery (PREOPRAD)
Randomized Phase II/III Study Comparing Preoperative Radiosurgery Versus Postoperative Radiosurgery in Patients With Brain Metastases Eligible for Surgery: Correlation With Histopathological Factors and Radiomic Analysis.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
- Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy.
- Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity.
- Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications.
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
研究概览
地位
详细说明
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Badajoz
-
Badajoz、Badajoz、西班牙、06080
- 尚未招聘
- Hospital Universitario de Badajoz
-
接触:
- Victoria Vera Barragán, MD
- 电话号码:+34924 21 81 00
- 邮箱:victoria.vera@salud-juntaex.es
-
-
Galicia
-
Vigo、Galicia、西班牙、36214
- 尚未招聘
- Hospital do Meixoeiro
-
接触:
- Beatriz Vazquez Barreiro, MD
- 电话号码:+34 986 81 11 11
- 邮箱:Beatriz.vazquez.barreiro@sergas.es
-
-
Madrid
-
Madrid、Madrid、西班牙、28034
- 招聘中
- Hospital Universitario Ramón y Cajal
-
接触:
- Eva Lizarbe Fernández, MD
- 电话号码:+3491 336 82 22
- 邮箱:eva.lizarbe@gmail.com
-
Madrid、Madrid、西班牙、28034
- 尚未招聘
- Hospital Ruber Internacional
-
接触:
- Rafael Garcia Garcia, MD
- 电话号码:+34913 87 50 00
- 邮箱:rafael.garciag.ce@ruberinternacional.es
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- 招聘中
- Hospital Universitario de Navarra
-
接触:
- Paola Anna Jablonska, MD
- 电话号码:+34848 428 482
- 邮箱:paolajablonska@gmail.com
-
接触:
- Cristina Gutierrez, PhD
- 电话号码:+34848433454
- 邮箱:cristina.gutierrez.povedano@navarra.es
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed solid tumor with one to four brain metastases.
- At least one brain metastasis considered suitable for surgical resection and stereotactic radiosurgery.
- Karnofsky Performance Status (KPS) ≥70.
- Life expectancy ≥3 months.
- Ability to undergo MRI examinations.
- Written informed consent provided.
Exclusion Criteria:
- Brain metastases from small-cell lung cancer, germ cell tumors, lymphoma, or leukemia.
- Prior radiotherapy to the index lesion.
- Leptomeningeal disease at baseline.
- Contraindication to surgery or stereotactic radiosurgery.
- Pregnancy or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation or evaluation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:preoperative radiosurgery
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
其他名称:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
|
其他:postoperative radiosurgery
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed |
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
其他名称:
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Locoregional adverse event-free survival
大体时间:From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed. |
From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Meningeal Failure Rate
大体时间:6 and 12 months after randomization.
|
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI). |
6 and 12 months after randomization.
|
|
Symptomatic Radiation Necrosis Rate
大体时间:6 and 12 months after randomization.
|
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation. |
6 and 12 months after randomization.
|
|
Local Control Rate
大体时间:6 and 12 months after randomization.
|
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI. |
6 and 12 months after randomization.
|
|
Distant Brain Failure-Free Survival
大体时间:6 and 12 months after randomization.
|
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s). |
6 and 12 months after randomization.
|
|
Overall Survival
大体时间:6 and 12 months after randomization.
|
Time from randomization to death from any cause. |
6 and 12 months after randomization.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Whole-Brain Radiotherapy (WBRT)
大体时间:From randomization until administration of WBRT, up to 42 months.
|
Time from randomization to the administration of whole-brain radiotherapy (WBRT). |
From randomization until administration of WBRT, up to 42 months.
|
|
Health-Related Quality of Life
大体时间:Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden). |
Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
|
|
Length of Hospital Stay
大体时间:From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge. |
From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
|
|
Treatment Delay
大体时间:From treatment planning to treatment completion, up to 42 months.
|
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment. |
From treatment planning to treatment completion, up to 42 months.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.